drugset / Trial / NCT02197975

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

NCT02197975

Phase 1 Completed 20 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days.

Timeline

Start
2014-08
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Budesonide Small molecule 320 ug Inhaled
Subject Formoterol Other / unclassified 9.6 ug Inhaled
Subject Glycopyrrolate Small molecule 18 ug Inhaled